| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 304.61% | £283,227.43 |
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 303.53% | £282,470.48 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 210.73% | £217,510.63 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 32.41% | £92,686.55 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 22.89% | £86,025.06 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | 2.76% | £71,930.65 |
| Lord Mance |
|
Stryker / NYQ:SYK | 1.87% | £71,305.82 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -6.06% | £65,760.89 |
| Baroness Deech |
|
Smith & Nephew / NYQ:SNN | -6.90% | £65,167.56 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -7.94% | £64,442.79 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -45.31% | £38,282.01 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** | |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -64.05% | £25,166.16 |